Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate
L. Bonello, U.S. Tantry, and R. Marcucci Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization
DOI 10.1016/j.jacc.2004.08.060, PII S0735109704017528
D.E. Kandzari, P.B. Berger, and A. Kastrati ISAR-REACT Study Investigators. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization J Am Coll Cardiol 44 2004 2133 2136 (Pubitemid 39576031)
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: Results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR Platelets) Study
DOI 10.1161/01.CIR.0000157138.02645.11
P.A. Gurbel, K.P. Bliden, K.A. Zaman, J.A. Yoho, K.M. Hayes, and U.S. Tantry Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study Circulation 11 2005 1153 1159 (Pubitemid 40365477)
(2005)Circulation, vol.111, Issue.9, pp. 1153-1159
The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses
DOI 10.1080/09537100701694144, PII 790792901
H.M. Judge, R.J. Buckland, and A. Sugidachi The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses Platelets 19 2008 125 133 (Pubitemid 351302377)